Trials / Withdrawn
WithdrawnNCT02872519
PET Imaging of Ovarian Carcinoma With 18F-FSPG
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Vanderbilt-Ingram Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial studies positron emission tomography (PET) imaging utilizing 18F-FSPG \[(S)-4-(3-\[18F\]Fluoropropyl)-L-glutamic acid\], a glutamic acid derivative, to image patients with ovarian cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose ovarian cancer and find out how far the disease has spread.
Conditions
- Stage IIIA Fallopian Tube Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA Primary Peritoneal Cancer
- Stage IIIB Fallopian Tube Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Primary Peritoneal Cancer
- Stage IIIC Fallopian Tube Cancer
- Stage IIIC Ovarian Cancer
- Stage IIIC Primary Peritoneal Cancer
- Stage IV Fallopian Tube Cancer
- Stage IV Ovarian Cancer
- Stage IV Primary Peritoneal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) | Given by IV |
| PROCEDURE | Positron Emission Tomography | Undergo scan |
| OTHER | Laboratory Biomarker Analysis | Laboratory Biomarker Analysis |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2019-08-01
- Completion
- 2020-08-01
- First posted
- 2016-08-19
- Last updated
- 2018-06-06
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02872519. Inclusion in this directory is not an endorsement.